This paper proposes the establishment of "Medical Artificial Intelligence (AI) Types (MA Types)" that classify AI in medicine not only by technical system requirements but also implications to healthcare workers' roles and users/patients. MA Types can be useful to promote discussion regarding the purpose and application of the clinical site. Although MA Types are based on the current technologies and regulations in Japan, but that does not hinder the potential reform of the technologies and regulations. MA Types aims to facilitate discussions among physicians, healthcare workers, engineers, public/patients and policymakers on AI systems in medical practices.
Introduction
The enthusiasm for introducing artificial intelligence (AI) to support physicians is rising as some systems perform on par with human beings in certain clinical settings [1, 10] . AI and machine learning are expected to transform the medical and healthcare insurance (49.4%) are the main sources (patient burden is 11.6%) 2 .
As for social insurance, it is virtually compulsory in Japan, so the ratio of public expenditure is high.
In addition, social insurance is deducted from income, so revenues do not increase unless GDP and income expand due to economic growth. At present, in fact, Japan's economic growth has been declining, currently at a rate of roughly 3%, compared with the average of around 9% in the 1960s and around 4% after the oil crisis. Furthermore, Japan is now moving from an aging society to a super-aging society. The percentage of the population aged 65 and older was 17.4% in 2000 but rose to 26.6% in 2015 and is expected to rise 36.8% by 2045 (21.4% of those aged 75 and older) 3 . Japan's medical system was premised on the levels of income growth and economic growth of the1960s; however, the country now faces a super-aging society and economic stagnation and therefore Japanese medical system is now in crisis.
Governmental Initiatives on Medical AI Implementation
The shortage of doctors in certain medical departments and regions, as well as overwork of doctors, have become issues in Japan. Since 2017, the Ministry of Health, Labour and Welfare (MHLW) organized the "study group on reforming working styles of doctors" 4 . The utilization of IT and artificial intelligence (AI) is expected to reduce the workload of medical practitioners, and ensure the quality of medical care. However, as in other countries, the implementation of AI in medicine and health care is a challenge in Japan. Especially, medical AI has issues such as data sharing and privacy, standardization and patient safety [6] .
In the "Healthcare 2035 report" compiled by the MHLW in 2015, the improvement of the quality, value, safety, and performance of medical care using ICT was mentioned as an objective, but it was also pointed out that ICT introduction has not progressed 5 . In 2016, "the Council for the Promotion of ICT Utilization in Health Care" compiled a proposal in the MHLW and the "AI Utilization Promotion Council of Health and Medical Care" established in 2017 selected six priority areas for AI development (genomic medicine, computer-aided diagnosis (CAD), diagnosis and treatment support, drug development, nursing care and dementia, and surgical support). In addition, the "AI Development Acceleration Consortium for Health and Medicine" was established under MHLW to examine problems and countermeasures on AI implementation in 2018. Along with those movements, the Japan Agency for Medical Research and Development (AMED) has promoted six academic societies (Japan Gastroenterological Endoscopy Society, The Japanese Society of Pathology, Japan Radiological Society, Japanese Ophthalmo-logical Society, Japanese Dermatological Association, and the Japan Society of Ultrasonics in Medicine) for building image databases to support AI diagnosis and treatment systems since 2017.
Index of Medical AI Systems
Various indices are used to discuss the development and implementation of medical AI systems. For technological indexing, AUC (area under the curve) based on the evaluation of machine learning is used. There is a technical report that guides and interprets medical electrical equipment and medical electrical systems employing a degree of autonomy from full manual (1) to full autonomy (10) 6 . The Japanese governmental organization Pharmaceuticals and Medical Devices Agency (PMDA) also categorizes Computer Assisted Diagnosis (CAD) systems into five levels -from a system that measures and presents features associated with disease and supports diagnosis (Level 1) to fully automatic diagnosis based on multi-modal information (diagnosis without assistance from physicians: Level 5) 7 . However, technological availability will not go directly to full automation with no human backup of clinicians. A recent review drew a nice analogy between self-driving cars and medicine, and suggested that full autonomy (Level 5) in medicine would never be attained, asserting medical AI would not surpass Level 3 conditional automation, for which humans (clinicians) will be required for oversight of algorithmic interpretation of images and data [16] .
Our question is, then, what is the "condition" that enables clinicians to trust AI? To facilitate discussion among stakeholders to implement AI systems in clinical settings, the accuracy of AI technology alone is not enough to gain the trust and understanding of other stakeholders. Therefore, in addition to technical requirements, we have developed a classification system that includes the perspectives of user interface, institutional design, and the role and impact on health professionals and patients/users.
Scope and Perspectives of MA Types
Social systems differ in countries and can constrain the social implementation of the technologies. In December 2018, the Japanese Ministry of Health, Labor and Welfare's (MHLW) Health Policy Bureau issued a notification declaring that "AI is only a support tool that raises the efficiency of judgment and input information in the sub-step of physician's judgment in the clinical process," and "the subject of the judgment is a physician, at least for the time being 8 . 6 webstore.iec.ch/preview/info_iec60601-4-1%7Bed1.0%7Den.pdf 7 www.pmda.go.jp/files/000225407.pdf 8 www.mhlw.go.jp/content/10601000/000468150.pdf This notification was issued based on a report "Research on clinical support using ICT such as AI 9 ." This report shows the current clinical process in medical institutions in a chronological order. According to this, the clinical process consists of the following four "steps" (inquiry, examination, diagnosis and treatment) and three "sub-steps" (planning examination strategy, planning diagnostic hypotheses, and planning treatment strategy) in between during consultation and exitus. "Steps" in which the clinical process should be carried out by the physicians, and "substeps" in which the physicians take the initiative in making the decision. AI is a support tool that raises the efficiency of "substeps" and presents information in relation to the provision of Article 17 of the Medical Act in Japan (Figure 1 ).
Perspective on Type Classification
Based on the present situation of AI implementation in the clinical field in Japan, the Medical AI Types (MA types) classification was carried out on the medical practice step considering the gradual introduction (Table 1 ). MA Type A is an autotext system that supports the acquisition and input of patient information, contributing to clinical support. It reduces the physician's task of obtaining and entering patient information. Type B is a secondary clinical support where physicians provide medical care with the AI system support. The difference between Type B and C is that while physicians do the analysis first in Type B, machines do the analysis first in Type C. In Type C, initial use of AI analysis results will reduce the burden on physicians' time and resources for interpretation.
Types A, B and C are considered as "sub-step" of the clinical support. On the other hand, Types D, E and F are considered clinical automation, which is a "step" replacing physicians' tasks. Type D is advanced clinical automation allowing physicians who do not have mature knowledge in a field to perform medical activities with the support of the AI medical system. The system 9 www.mhlw.go.jp/content/10601000/000468448.pdf. The final report was released on January 2019 and available from: mhlw-grants.niph.go.jp/niph/search/NIDD00.do?resrchNum=201721055A will allow patients to receive medical care in areas where there are no specialists available and equalize the quality of medical care. Type D still requires the physician; however, Type E and F are fully automated medical care types and need not physicians in the clinical process. The difference between Type E and F is that Type E can be used in specific locations (e.g. pharmacies and opticians) with the support of medical staff, whereas Type F can be used anywhere, possibly using apps.
In Japan, because of the notification by the MLHW, medical institutions mainly provide medical care covered by health insurance. Therefore, Types D, E and F are not approved to be used as medical AI at present 10 . However, research and development are promoted in clinical support (Type A, B and C). Table 2 shows specific examples of clinical support (Type A, B, C) currently developed in Japan. Each example is arranged by the sub-steps located in current medical systems (clinical support: planning examination strategy, planning diagnostic hypotheses, and planning treatment strategy). This type classification was developed based on interviews and discussions among physicians, health professionals, technology developers, users, and policy-makers 11 .
Relationships among Physicians, Users, and Machine
AI systems and the physician must work together [17] but their role is in graduation. Figure 2 illustrates the relationship between doctor, patient/user and medical AI systems from MA types A to F. Each stage of the clinical process includes "input (of patient and user information)," "analysis (by a physician and/or AI)" and "Output (presentation of results such as diagnosis)." These are conducted in each clinical process, but some cases involve combinations of examination, diagnosis, and treatment. 10 Even though that clinical automation (Type D, E and F) are not approved to be used as medical AI, if the service is considered as health care system which is outside the current medical insurance system, automated health care systems already exist in Japan. 11 "AI x Medicine seminar" has been organized by authors, inviting physicians, engineers, policy makers since January 2019. (ifi.u-tokyo.ac.jp/projects/medical-ai/).
Figure 1: "
Step" and "sub-step" of clinical process. AI as a tool will support physicians' clinical processes. This is a step model and the boundaries of this process may be vague depending on the medical department. This paper mainly focuses on AI use in clinical process and will not deal with operations outside (e.g. support and automation of peripheral tasks such as document arrangement, which is not involved in the diagnosis by physicians or surgical robots that perform treatment.) In addition, preventive medical care, follow-up after leaving hospital, and diagnostic treatment are not included in the MA type classification because they are outside the above steps. However, we consider that the application of the type classification is possible.
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Table 1: Medical AI Types (MA Types). MHLW notification issued in December 2018 clearly states that the AI system can only be used as clinical support (sub-steps) and that the final decision is made by a physician.
Discussions and Suggestions
We chose the terminology "types" rather than "levels" based on the feedback from physicians. Their concern was that selecting the term "levels" in the automobile analogy ends up with a metamessage towards full automation, that is, aiming the physician's absence. Using the term "types" weakens its directionality and indicates that each type is independent. On the other hand, there are disadvantages to using the term "types." For example, in a situation where the accuracy of technology is insufficient and the legal systems are not keeping up, it is important to implement even Type B technology. However, it should be noted that there is a concern that Type B, which occurs only during the transition period, may take root and impede the transition to Type C.
Despite the disadvantages described above, this type of classification is useful for sharing awareness among health professionals, technology developers and policy makers when determining clinical objectives and applications to implement appropriate AI systems. Three example cases to use this classification are shown to promote implementation of AI medical systems.
Utilize MA Types to Promote Shared Awareness among Stakeholders according to Purposes and Applications
The requirements for medical AI systems vary depending on the clinical purposes and applications. Depending on the magnitude of risk and ripple effects, with the classification, it will become possible to discuss the types that each clinical department and academic society should aim for. For example, in the case of Type B, which prevents oversight, it is useful for health professionals even if the recognition accuracy is not high when it takes the role of an alert.
Type changes depending on the usage, even if the technological systems and accuracy are the same. Also, not only AI accuracy but also the appropriate UI design should be considered. For example, in a case where AI is used for the purpose of double checking the digestive endoscopy diagnosis support, Type B (secondary support) can be used, but in the case where AI supports an examination such as showing specific location of cancer during the examination, Type C (primary support) would be preferred. Therefore, by identifying the MA type from the purpose and the application, the recognition of required MA Types should be shared among the stakeholders to proceed development and implementation. 
Utilize MA Types to Construct Real-World Data that Can be Used Effectively
In recent years, there has been a push towards the use of "realworld data" which is data generated in the clinical practice 12 . However, in many cases, some devices such as electronic medical records are not structured in a form that facilitates secondary use of data, and interoperability across multiple platforms becomes an issue. Therefore, difficulty has been pointed out to utilize machine learning for AI development from Type B to F.
On the other hand, in Type A (autotext system), the AI system supports the acquisition and input of patient information that contributes to medical care. As a result, medical information is digitized and accumulated. Therefore, in the development of Type A, the secondary use of data should be promoted to improve the quality of medical care and medical management, considering the structure of data.
Utilize MA Types to Promote Institutional Reforms toward Patient-Centered Medicine
Lastly, patient-centered medicine is becoming the main-stream worldwide as opposed to the medical institutions centered medicine [2] . Also, there is a trend, particularly in Europe, to recognize the right of patients to control their own information 13 . Whereas in Japan, which has entered a super-aging society ahead of the rest of the world, preventive medical care and measures against chronic diseases have become important, and medical system is being reviewed 14 . 12 The promotion of true patient-centered medicine requires not only clinical support (Types A, B, and C), which reduce the burden of healthcare professionals, but also the use of clinical automation (Types D, E, and F), which benefits of patients appear. Types D, E, and F are not covered by the current medical insurance system in Japan, therefore medical system reform is requiring to make patient-centered medicine. In fact, there are countries that are promoting MA Type D in areas such as medical consultation recommendations and healthcare 15 . 15 We consider that IDX-DR (www.eyediagnosis.net/) can be categorized as Type D. 
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Conclusion
Despite the enthusiasm for introducing decision-support systems in clinical practices, several complexities such as incompatibility with the traditional routine workflow and scarce resources are limiting their introduction [14, 18] . In addition, the technical and institutional environment surrounding medicine, health professionals and patients are expected to continuously change. Current laws also may change in order to maximize the potential value of AI [13] .
In the age of transition, trust among patients and physicians has become essential [11] , and based on this MA types, it is expected that discussions will be promoted by each related stakeholders and department by recognizing the limitations and possibilities of AI medical systems. Having a systematic way to refer to the types of AI at each step is beneficial to patients, regulators and technicians, providing an efficient and accurate way to communicate about it. Streamlining the conversation and providing common context will also go a long way to building trust in the systems as people feel confident in their understanding of the various types of medical AI interventions.
